10x Genomics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-6.2%projected annual EPS growth
Analyst Coverage
13analysts covering
FY Revenue (est.)
$619.9Mnext fiscal year
FY EPS (est.)
$0.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Consumables Revenue Quarterly507.2MTarget: Double-digit growth in FY 2026
Cumulative Instruments Sold Quarterly8KTarget: Continued expansion of global install base
Gross Margin Quarterly70.0%Target: Maintain or expand above 70%
Watch Items
- Atera Platform Commercial RolloutTrigger: Initial shipments scheduled for H2 2026Action: Monitor preorder conversion rates, production capacity constraints, and initial customer feedback on spatial whole-transcriptome performance.
- Academic and Translational Funding EnvironmentTrigger: Persistent budget constraints in the U.S. and EuropeAction: Track instrument sales volumes and average selling prices (ASPs) to assess if funding headwinds are easing.
- Competitive Dynamics in Spatial BiologyTrigger: Aggressive product cycles and consolidation (e.g., Bruker's acquisition of NanoString assets)Action: Evaluate Xenium and Visium HD market share relative to competing platforms.
Research as of 20 Jun 2026